The advancements in precision medicine have enabled healthcare organizations to significantly improve their cancer treatment capabilities.
FREMONT, CA: The advancements in the healthcare sector over the last few years have significantly enhanced cancer treatment. Practitioners are leveraging a combination of technologies, including radiation, surgery, chemotherapy, and several other treatments to increase the rate of survival among cancer patients. However, most of the investment is focused on the development of precision medicine for cancer treatment.
In the precision medicine landscape, the efforts of Kura Oncology are unparalleled. The clinical-stage biopharmaceutical company strives to enhance cancer treatment with innovation and efficiency. Recently, it received patents from the U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO) securing its primary drug candidate, tipifarnib. The potent and selective farnesyl transferase inhibitor is being studied in multiple solid tumors and hematologic indications, including a registration-directed clinical trial in HRAS mutant head and neck squamous cell carcinoma (HNSCC).
“Along with advancing the development of tipifarnib in multiple, biomarker-defined patient populations, securing robust intellectual property protection to provide commercial exclusivity in major commercial markets are an important part of our overall corporate strategy,” Wilson said. “In this regard, we are pleased to announce new U.S. and European patents that cover the treatment of HRAS mutant HNSCC and NSCLC patients as well as the issuance of a first U.S. patent that extends our patent exclusivity to the use of any farnesyl transferase inhibitor for the treatment of HRAS mutant HNSCC patients. We believe these patents strengthen our competitive advantage as we continue to advance the development of tipifarnib, and we intend to continue to aggressively pursue additional intellectual property protection, both in the U.S. and abroad, ” said Troy Wilson, President & CEO of Kura Oncology.
The patents will enable the company to expand the protection for tipifarnib and secure counterpart patents in foreign countries. Kura Oncology is committed to its goal of developing effective precision medicine for cancer treatment. Its pipeline comprises small molecule drug candidates that target cancer signaling pathways having robust scientific and clinical rationale to enhance outcomes by identifying patients most likely to benefit from the treatment. The company is conducting a registration-directed trial for tipifarnib in recurrent or metastatic patients with HRAS mutant HNSCC.
“We are also conducting preclinical development activities for KO-539 with the goal to file an IND and advance this drug candidate into Phase 1 human clinical testing,” mentioned Wilson. “The ultimate of Kura Oncology is to identify indications with the potential for single-agent activity, which may enable accelerated development.”